CMTR1 promotes colorectal cancer cell growth and immune evasion by transcriptionally regulating STAT3

A-Bin You1,2, Hu Yang1,2, Chun-Ping Lai1,2

  • 1Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, 361003, China.

Cell Death & Disease
|April 6, 2023
PubMed

Insights

CMTR1 is a novel oncogene in colorectal cancer (CRC) that drives tumor growth and suppresses anti-tumor immunity. Reducing CMTR1 inhibits CRC progression and enhances immunotherapy effectiveness by boosting CD8+ T cell infiltration.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • CMTR1 (IFN-stimulated gene 95 kDa protein) is upregulated during viral infections.
  • The role of CMTR1 in colorectal cancer (CRC) tumorigenesis and immune regulation is largely unknown.

Purpose of the Study:

  • To investigate the function of CMTR1 in colorectal cancer.
  • To determine CMTR1's impact on tumor growth and the tumor immune microenvironment.

Main Methods:

  • Analysis of The Cancer Genome Atlas (TCGA) and human tissue microarrays (TMA).
  • In vitro and in vivo knockdown (KD) and overexpression experiments.
  • KEGG pathway analysis and investigation of STAT3 signaling.
  • Assessment of CD8+ T cell infiltration and PD1 blockade immunotherapy efficacy.

Main Results:

  • CMTR1 expression is significantly higher in CRC tissues and correlates with poor prognosis.
  • CMTR1 knockdown suppresses CRC cell proliferation and tumorigenicity; overexpression enhances them.
  • CMTR1 KD impacts the JAK/STAT signaling pathway by inhibiting STAT3 expression and activation.
  • CMTR1 KD enhances PD1 blockade immunotherapy efficacy through increased CD8+ T cell infiltration.

Conclusions:

  • CMTR1 acts as a novel oncogene in colorectal cancer.
  • CMTR1 plays a critical role in regulating tumor cell proliferation and suppressing antitumor immunity.
  • Targeting CMTR1 may represent a therapeutic strategy to improve CRC treatment and immunotherapy outcomes.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.0K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K